News Releases Year None202320222021 September 26, 2023 YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine September 15, 2023 YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection September 5, 2023 YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference August 24, 2023 YS Biopharma Announces Purchase of Shares by Company Officers August 15, 2023 YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 August 10, 2023 YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 July 26, 2023 YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 July 21, 2023 YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 June 1, 2023 YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA May 18, 2023 YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 Pagination Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds Contact IR
Year None202320222021 September 26, 2023 YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine September 15, 2023 YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection September 5, 2023 YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference August 24, 2023 YS Biopharma Announces Purchase of Shares by Company Officers August 15, 2023 YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 August 10, 2023 YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 July 26, 2023 YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 July 21, 2023 YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 June 1, 2023 YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA May 18, 2023 YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 Pagination Current page 1 Page 2 Next page next › Last page last »